drugset / Trial / NCT00367276

Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 mg/DRSP 3 mg) on Quality of Life.

NCT00367276

Phase 3 Completed 221 enrolled Bayer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effects on the quality of life and BMI of new contraceptives.

Timeline

Start
2002-12
Primary completion
Completion
2004-05

Drugs

EvaluationDrugModalityDoseRoute
Subject drospirenone Unknown 3 mg Oral
Subject ethinyl estradiol Small molecule 30 ug Oral

Indications

No indication recorded.